Get started
Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ORMP chart


Full chart

ORMP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪97.44 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
4.56
Basic EPS (TTM)
0.51 USD
Net income (FY)
‪5.53 M‬ USD
Revenue (FY)
‪1.34 M‬ USD
Shares float
‪34.77 M‬
Beta (1Y)
1.25

Employees


Employees (FY)
15
Change (1Y)
−2 −11.76%
Revenue / Employee (1Y)
‪89.33 K‬ USD
Net income / Employee (1Y)
‪368.33 K‬ USD

About Oramed Pharmaceuticals Inc.


Sector
Health Technology
CEO
Nadav Kidron
Headquarters
New York
Website
oramed.com
Founded
2002
FIGI
BBG000LRYR36
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ORMP news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ORMP is 2.39 USD — it has increased by 3.02% in the past 24 hours. Watch Oramed Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oramed Pharmaceuticals Inc. stocks are traded under the ticker ORMP.
ORMP stock has risen by 1.27% compared to the previous week, the month change is a −0.83% fall, over the last year Oramed Pharmaceuticals Inc. has showed a 34.27% increase.
We've gathered analysts' opinions on Oramed Pharmaceuticals Inc. future price: according to them, ORMP price has a max estimate of 3.25 USD and a min estimate of 3.25 USD. Watch ORMP chart and read a more detailed Oramed Pharmaceuticals Inc. stock forecast: see what analysts think of Oramed Pharmaceuticals Inc. and suggest that you do with its stocks.
ORMP reached its all-time high on Jan 13, 2014 with the price of 31.73 USD, and its all-time low was 0.09 USD and was reached on Apr 2, 2004. View more price dynamics on ORMP chart.
See other stocks reaching their highest and lowest prices.
ORMP stock is 4.31% volatile and has beta coefficient of 1.25. Track Oramed Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Oramed Pharmaceuticals Inc. there?
Today Oramed Pharmaceuticals Inc. has the market capitalization of ‪97.44 M‬, it has increased by 2.12% over the last week.
Yes, you can track Oramed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Oramed Pharmaceuticals Inc. is going to release the next earnings report on Nov 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ORMP earnings for the last quarter are 0.22 USD per share, whereas the estimation was 0.01 USD resulting in a ‪2.10 K‬% surprise. The estimated earnings for the next quarter are 0.01 USD per share. See more details about Oramed Pharmaceuticals Inc. earnings.
Oramed Pharmaceuticals Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪250.00 K‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
ORMP net income for the last quarter is ‪9.21 M‬ USD, while the quarter before that showed ‪1.54 M‬ USD of net income which accounts for 499.74% change. Track more Oramed Pharmaceuticals Inc. financial stats to get the full picture.
No, ORMP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 15.00 employees. See our rating of the largest employees — is Oramed Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oramed Pharmaceuticals Inc. EBITDA is ‪−12.65 M‬ USD, and current EBITDA margin is ‪−1.16 K‬%. See more stats in Oramed Pharmaceuticals Inc. financial statements.
Like other stocks, ORMP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oramed Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oramed Pharmaceuticals Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oramed Pharmaceuticals Inc. stock shows the sell signal. See more of Oramed Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.